Skip to main content
Top
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Research

Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer

Authors: Shahab Uddin, Rong Bu, Maqbool Ahmed, Jehad Abubaker, Fouad Al-Dayel, Prashant Bavi, Khawla S Al-Kuraya

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Background

Recent epidemiological studies have suggested that obesity is associated with ovarian cancer. Obesity hormone leptin and its receptor (Ob-R) contribute to tumor development by enhancing cell growth and survival. This study was design to investigate the prevalence of leptin and Ob-R in Middle Eastern epithelial ovarian cancer (EOC) and to analyze the role of leptin and the mechanisms under its action in EOC tissue sample and cell lines.

Methods

The expression of leptin and Ob-R was examined by immunohistochemistry in a tissue microarray of 156 EOC samples. Proliferation of EOC cells in response to leptin was assessed by MTT assays, and its anti-apoptotic effects were determined by flow cytometry. Effect of leptin on PI3K/AKT signaling pathway was further determined by western blotting.

Results

In clinical samples, Ob-R overexpression was seen in 59.2% EOCs and was significantly associated with poor progression free survival (p = 0.0032). Furthermore, Ob-R expression was associated with anti apoptotic proteins Bcl-XL (p = 0.0035) and XIAP (p = 0.0001). In vitro analysis using EOC cell lines showed that leptin stimulated cell proliferation and inhibits apoptosis via activation of PI3K/AKT signaling pathway. Inhibition of PI3K activity by LY294002, a specific inhibitor of PI3-kinase abrogated leptin mediated PI3K/AKT signaling. Gene silencing of Ob-R with Ob-R siRNA in EOC cells resulted in down regulation of phospho-AKT and its down stream targets.

Conclusion

Our findings have potential clinical implication for EOC development and progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001, 22: 255-258. 10.1210/er.22.2.255PubMed Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001, 22: 255-258. 10.1210/er.22.2.255PubMed
2.
go back to reference Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H: Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology. 2005, 68: 293-298. 10.1159/000086967CrossRefPubMed Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H: Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology. 2005, 68: 293-298. 10.1159/000086967CrossRefPubMed
3.
go back to reference McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998, 25: 340-348.PubMed McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998, 25: 340-348.PubMed
4.
go back to reference Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007, 4: 195-208. 10.3747/co.2007.148. 10.3747/co.2007.148CrossRef Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007, 4: 195-208. 10.3747/co.2007.148. 10.3747/co.2007.148CrossRef
5.
go back to reference Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67: 2497-2507. 10.1158/0008-5472.CAN-06-3075PubMedCentralCrossRefPubMed Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67: 2497-2507. 10.1158/0008-5472.CAN-06-3075PubMedCentralCrossRefPubMed
6.
go back to reference Abu-Abid S, Szold A, Klausner J: Obesity and cancer. J Med. 2002, 33: 73-86.PubMed Abu-Abid S, Szold A, Klausner J: Obesity and cancer. J Med. 2002, 33: 73-86.PubMed
7.
go back to reference Ognunwobi OO, Bealses LP: The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis. 2007, 22: 401-409. 10.1007/s00384-006-0181-yCrossRef Ognunwobi OO, Bealses LP: The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis. 2007, 22: 401-409. 10.1007/s00384-006-0181-yCrossRef
8.
go back to reference Choi JH, Park SH, Leung PC, Choi KC: Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2005, 90: 207-210. 10.1210/jc.2004-0297CrossRefPubMed Choi JH, Park SH, Leung PC, Choi KC: Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2005, 90: 207-210. 10.1210/jc.2004-0297CrossRefPubMed
9.
10.
go back to reference Bouloumié A, Drexler HC, Lafontan M, Busse R: Leptin, the product of Ob gene, promotes angiogenesis. Circ Res. 1998, 83: 1059-1066.CrossRefPubMed Bouloumié A, Drexler HC, Lafontan M, Busse R: Leptin, the product of Ob gene, promotes angiogenesis. Circ Res. 1998, 83: 1059-1066.CrossRefPubMed
11.
go back to reference Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR: Biological action of leptin as an angiogenic factor. Science. 1998, 281: 1683-1686. 10.1126/science.281.5383.1683CrossRefPubMed Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR: Biological action of leptin as an angiogenic factor. Science. 1998, 281: 1683-1686. 10.1126/science.281.5383.1683CrossRefPubMed
12.
go back to reference Bjørbaek C, Uotani S, da Silva B, Flier JS: Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997, 272: 32686-32695. 10.1074/jbc.272.51.32686CrossRefPubMed Bjørbaek C, Uotani S, da Silva B, Flier JS: Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997, 272: 32686-32695. 10.1074/jbc.272.51.32686CrossRefPubMed
14.
go back to reference Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, Schatzkin A, Lacey JV: Body mass index and risk of ovarian cancer. Cancer. 2009, 115: 812-822. 10.1002/cncr.24086PubMedCentralCrossRefPubMed Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, Schatzkin A, Lacey JV: Body mass index and risk of ovarian cancer. Cancer. 2009, 115: 812-822. 10.1002/cncr.24086PubMedCentralCrossRefPubMed
15.
go back to reference Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG: Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res. 2005, 11: 3102-3108. 10.1158/1078-0432.CCR-04-1857CrossRefPubMed Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG: Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res. 2005, 11: 3102-3108. 10.1158/1078-0432.CCR-04-1857CrossRefPubMed
16.
go back to reference Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S: Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol. 2007, 60: 902-906. 10.1136/jcp.2006.041004PubMedCentralCrossRefPubMed Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S: Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol. 2007, 60: 902-906. 10.1136/jcp.2006.041004PubMedCentralCrossRefPubMed
17.
go back to reference Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine. 2006, 33: 66-71. 10.1016/j.cyto.2005.11.015CrossRefPubMed Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine. 2006, 33: 66-71. 10.1016/j.cyto.2005.11.015CrossRefPubMed
18.
go back to reference Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M, Sulkowski S: Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann N Y Acad Sci. 2007, 1095: 90-98. 10.1196/annals.1397.013CrossRefPubMed Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M, Sulkowski S: Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann N Y Acad Sci. 2007, 1095: 90-98. 10.1196/annals.1397.013CrossRefPubMed
19.
go back to reference Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of leptin and leptin receptor [OB-R] in human breast cancer. Clin Cancer Res. 2004, 10: 4325-4331. 10.1158/1078-0432.CCR-03-0749CrossRefPubMed Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of leptin and leptin receptor [OB-R] in human breast cancer. Clin Cancer Res. 2004, 10: 4325-4331. 10.1158/1078-0432.CCR-03-0749CrossRefPubMed
20.
go back to reference Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. Natl Cancer Inst. 2002, 94: 1704-1711.CrossRef Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. Natl Cancer Inst. 2002, 94: 1704-1711.CrossRef
21.
22.
go back to reference Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE: Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg. 2007, 94: 346-354. 10.1002/bjs.5530CrossRefPubMed Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE: Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg. 2007, 94: 346-354. 10.1002/bjs.5530CrossRefPubMed
23.
go back to reference Ogunwobi OO, Beales IL: The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis. 2007, 22: 401-409. 10.1007/s00384-006-0181-yCrossRefPubMed Ogunwobi OO, Beales IL: The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis. 2007, 22: 401-409. 10.1007/s00384-006-0181-yCrossRefPubMed
24.
go back to reference Mitchell M, Armstrong DT, Robker RL, Norman RJ: Adipokines: implications for female fertility and obesity. Reproduction. 2005, 130: 583-597. 10.1530/rep.1.00521CrossRefPubMed Mitchell M, Armstrong DT, Robker RL, Norman RJ: Adipokines: implications for female fertility and obesity. Reproduction. 2005, 130: 583-597. 10.1530/rep.1.00521CrossRefPubMed
25.
go back to reference Chen C, Chang YC, Liu CL, Chang KJ, Guo IC: Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat. 2006, 98: 121-132. 10.1007/s10549-005-9139-yCrossRefPubMed Chen C, Chang YC, Liu CL, Chang KJ, Guo IC: Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat. 2006, 98: 121-132. 10.1007/s10549-005-9139-yCrossRefPubMed
26.
go back to reference Ogunwobi O, Mutungi G, Beales IL: Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactiv-ation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006, 147: 4505-4516. 10.1210/en.2006-0224CrossRefPubMed Ogunwobi O, Mutungi G, Beales IL: Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactiv-ation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006, 147: 4505-4516. 10.1210/en.2006-0224CrossRefPubMed
27.
go back to reference Russel P: Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract. Edited by: Kurman RJ. 1995, 705-782. New York: Springer-Verlag. Russel P: Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract. Edited by: Kurman RJ. 1995, 705-782. New York: Springer-Verlag.
28.
go back to reference Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS: Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 213: 190-199. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS: Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 213: 190-199.
29.
go back to reference Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS: Clinicopathological analysis of Papillary Thyroid Cancer with PIK3CA alterations in Middle Eastern Population. J Clin Endocrinol Metab. 2008, 93: 611-618. 10.1210/jc.2007-1717CrossRefPubMed Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS: Clinicopathological analysis of Papillary Thyroid Cancer with PIK3CA alterations in Middle Eastern Population. J Clin Endocrinol Metab. 2008, 93: 611-618. 10.1210/jc.2007-1717CrossRefPubMed
30.
go back to reference McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM: Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005, 11: 5188-5194. 10.1158/1078-0432.CCR-05-0158CrossRefPubMed McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM: Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005, 11: 5188-5194. 10.1158/1078-0432.CCR-05-0158CrossRefPubMed
31.
go back to reference Camp RL, Dolled-Filhart M, Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004, 10: 7252-7259. 10.1158/1078-0432.CCR-04-0713CrossRefPubMed Camp RL, Dolled-Filhart M, Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004, 10: 7252-7259. 10.1158/1078-0432.CCR-04-0713CrossRefPubMed
32.
go back to reference Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS: Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006, 108: 4178-4186. 10.1182/blood-2006-04-016907CrossRefPubMed Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS: Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006, 108: 4178-4186. 10.1182/blood-2006-04-016907CrossRefPubMed
33.
go back to reference Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS: Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008, 27: 3539-3545. 10.1038/sj.onc.1211013CrossRefPubMed Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS: Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008, 27: 3539-3545. 10.1038/sj.onc.1211013CrossRefPubMed
34.
go back to reference Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS: Bortezomib [Velcade] induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008, 68: 3379-3388. 10.1158/0008-5472.CAN-07-6109CrossRefPubMed Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS: Bortezomib [Velcade] induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008, 68: 3379-3388. 10.1158/0008-5472.CAN-07-6109CrossRefPubMed
35.
go back to reference Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S: Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther. 2008, 7: 3318-3329. 10.1158/1535-7163.MCT-08-0541CrossRefPubMed Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S: Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther. 2008, 7: 3318-3329. 10.1158/1535-7163.MCT-08-0541CrossRefPubMed
36.
go back to reference Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P, Al-Kuraya KS: S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008, 216: 483-494. 10.1002/path.2433CrossRefPubMed Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P, Al-Kuraya KS: S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008, 216: 483-494. 10.1002/path.2433CrossRefPubMed
37.
go back to reference Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A: Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA. 2004, 101: 47-152. 10.1073/pnas.0308725100. 10.1073/pnas.0308725100 Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A: Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA. 2004, 101: 47-152. 10.1073/pnas.0308725100. 10.1073/pnas.0308725100
Metadata
Title
Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer
Authors
Shahab Uddin
Rong Bu
Maqbool Ahmed
Jehad Abubaker
Fouad Al-Dayel
Prashant Bavi
Khawla S Al-Kuraya
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-74

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine